

**IN THE CLAIMS**

1. (Currently Amended): An optical sensor comprising:  
an optical source capable of being positioned on a tissue and emitting infrared light into the tissue at a plurality of selected wavelengths;  
a photodetector capable of detecting the selected wavelengths of light from the tissue, the photodetector being positioned on the tissue removed from the optical source but sufficiently close in proximity to the optical source to contact the same general tissue;  
an oscillator coupled to the optical source and providing radio frequency modulation of the optical source, the optical source being responsive to the radio frequency modulation by emitting the plurality of selected wavelengths, the selected wavelengths being selected to generate measurable changes in absorbance of analytes of interest within the tissue;  
and  
a wavelength modulator coupled to the oscillator and controlling radio frequency modulation of the optical source to emit the plurality of selected wavelengths that are selected to generate the measurable changes in absorbance of analytes of interest within the tissue.
2. (Original) An optical sensor according to Claim 1 further comprising:  
a demodulator coupled to the photodetector and capable of detecting phase changes of a signal indicative of the radio frequency modulation for the selected wavelengths of light passing through the tissue to measure path length.
3. (Canceled)

KOSTNER BERTANI LLP  
16662 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0260

4. (Currently Amended) An optical sensor according to Claim 3 1 further comprising:

the wavelength modulator being capable of varying the wavelength of the light entering the tissue for a plurality of measurements to reduce scattering errors.

5. (Currently Amended) An optical sensor according to Claim 3 1 further comprising:

the wavelength modulator being capable of varying the wavelength of the optical source by varying temperature of the optical source.

6. (Currently Amended) An optical sensor according to Claim 3 1 further comprising:

the wavelength modulator being capable of varying the wavelength of the optical source using a micro-electro-mechanical system (MEMS) forming a portion of the optical source.

7. (Currently Amended) An optical sensor according to Claim 3 1 further comprising:

the wavelength modulator being capable of varying the wavelength of the optical source by varying drive current of the optical source.

8. (Original) An apparatus comprising:

a single optical source capable of emitting infrared light into the tissue at a plurality of selected wavelengths;

a detector capable of detecting the selected wavelengths of light in response to emission by the optical source;

an oscillator coupled to the optical source and providing radio frequency modulation of the optical source and wavelength variation of the optical source in the range of  $\pm 1\%$  about the selected wavelengths; and

an analyzer coupled to the detector and coupled to the oscillator, the analyzer for analyzing changes in modulation intensity and phase between a signal

KOESTNER BERTANI LLP  
14652 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0250

from the optical source to the detector to measure absorbance of an analyte of interest within the tissue and determine concentration of the analyte according to an equation as follows:

$$\mu_a = \frac{\ln 10}{-2c} \left( \frac{\frac{dA}{d\mu_a}}{\frac{d\theta}{d\mu_a}} \right) = \frac{\ln 10}{-2c} \left( \frac{\Delta A}{\Delta \theta} \right)$$

where  $dA/d\mu_a$  is a measured modulation amplitude difference over a slope of absorbance and  $d\theta/d\mu_a$  is a measured phase change over the slope of absorbance, the slope of absorbance being defined from known absorbance characteristics of the analyte of interest over the selected wavelength variation range.

9. (Original) An apparatus according to Claim 8 wherein:  
the oscillator further comprises:  
a power supply; and  
a temperature controller.
10. (Original) An apparatus according to Claim 8 wherein:  
the analyzer is a demodulator capable of determining a phase difference  $\theta$  of modulation between the emitted light and the reflected light and an amplitude  $A$  of modulation of the reflected light determined with in-phase and quadrature demodulation parameters.
11. (Original) An apparatus according to Claim 8 wherein:  
the apparatus is a single wavelength pulse oximeter; and  
the optical source is a single laser diode with a wavelength range of 760nm to 850nm that is wavelength shifted approximately  $\pm 2.5$ nm, the slope of absorbance between the wavelength-shifted points being equal to a blood oxygen saturation value.

KOESTNER BERTANI LLP  
18662 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0260  
FAX (949) 251-0260

12. (Original) An apparatus according to Claim 8 wherein:  
the oscillator further comprises:  
a power supply; and  
a temperature controller; and  
the power supply and temperature controller are capable of activating and  
modulating the optical source to emit the selected wavelengths in a range  
of wavelengths within one percent of the first nominal wavelength and to  
emit the selected wavelengths in a range of wavelengths within one  
percent of a second nominal wavelength.
13. (Original) An apparatus according to Claim 12 wherein:  
the first nominal wavelength is 760 nm and is modulated between approximately  
+/- 5 nm;  
the second nominal wavelength is 800 nm and is modulated between  
approximately +/- 5 nm; and  
the first and second wavelengths measure oxyhemoglobin and deoxyhemoglobin  
concentration in tissue.
14. (Original) An apparatus according to Claim 13 further comprising:  
a processor coupled to the analyzer and capable of noninvasively monitoring  
oxyhemoglobin and deoxyhemoglobin concentrations in fetal brains, the  
monitored concentrations being indicative of fetal hypoxia during labor  
and delivery, the optical source and the detector being capable of  
attachment to the fetal skull after the mother's membranes break with a  
low level suction.
15. (Original) An apparatus according to Claim 13 further comprising:  
a processor coupled to the analyzer capable of measuring blood flow as a function  
of the difference between oxyhemoglobin concentration and  
deoxyhemoglobin concentration, the apparatus measuring blood flow  
noninvasively.

KDESTNER BERTANI LLP  
1660 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0260

16. (Original) An apparatus according to Claim 13 further comprising:  
a processor coupled to the analyzer capable of noninvasively measuring the  
concentrations so that measurements are made continuously and without  
risk of infection, bleeding, blood loss, or invasive procurement  
procedures.
17. (Original) An apparatus according to Claim 8 wherein:  
the oscillator is capable of activating and modulating the optical source to emit  
the selected wavelengths in a range of wavelengths within one percent of  
the first nominal wavelength, emit the selected wavelengths in a range of  
wavelengths within one percent of a second nominal wavelength, and emit  
the selected wavelengths in a range of wavelengths within one percent of a  
third nominal wavelength.
18. (Original) An apparatus according to Claim 17 wherein:  
the first nominal wavelength is 760 nm and is modulated between approximately  
+/- 5 nm;  
the second nominal wavelength is 800 nm and is modulated between  
approximately +/- 5 nm;  
the third nominal wavelength is 850 nm and is modulated between approximately  
+/- 5 nm; and  
the first, second, and third wavelengths measure oxyhemoglobin,  
deoxyhemoglobin, and ferritin concentrations in tissue.
19. (Original) An apparatus according to Claim 18 further comprising:  
a processor coupled to the analyzer capable of predicting patients at risk for acute  
respiratory distress syndrome that will progress to acute respiratory  
distress syndrome based on measurement of changes in ferritin  
concentration.

KOSTNER BERTANI LLP  
18602 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0260

20. (Original) An apparatus according to Claim 18 further comprising:  
a processor coupled to the analyzer capable of monitoring medication effects in  
acute respiratory distress syndrome patients.
21. (Original) An apparatus according to Claim 18 further comprising:  
a processor coupled to the analyzer capable of noninvasively measuring ferritin  
concentration with or without iron-binding proteins.
22. (Original) An apparatus according to Claim 17 wherein:  
the first nominal wavelength is 760 nm and is modulated between approximately  
+/- 5 nm;  
the second nominal wavelength is 800 nm and is modulated between  
approximately +/- 5 nm;  
the third nominal wavelength is 1620 nm and is modulated between  
approximately +/- 10 nm; and  
the first, second, and third wavelengths measure oxyhemoglobin,  
deoxyhemoglobin, and carbon dioxide concentrations in tissue.
23. (Original) An apparatus according to Claim 22 wherein:  
the apparatus is capable of measuring oxyhemoglobin, deoxyhemoglobin, and  
carbon dioxide concentration noninvasively in tissue.
24. (Original) An apparatus according to Claim 8 wherein:  
the oscillator is capable of activating and modulating the optical source to emit  
the selected wavelengths in a range of wavelengths within one percent of  
the first nominal wavelength, emit the selected wavelengths in a range of  
wavelengths within one percent of a second nominal wavelength, emit the  
selected wavelengths in a range of wavelengths within one percent of a  
third nominal wavelength, and emit the selected wavelengths in a range of  
wavelengths within one percent of a fourth nominal wavelength.

KOESTNER BERTANI LLP  
18862 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0251

25. (Original) An apparatus according to Claim 24 wherein:  
the first nominal wavelength is 760 nm and is modulated between approximately  
+/- 5 nm;  
the second nominal wavelength is 800 nm and is modulated between  
approximately +/- 5 nm;  
the third nominal wavelength is 850 nm and is modulated between approximately  
+/- 5 nm; and  
the fourth nominal wavelength is 1620 nm and is modulated between  
approximately +/- 10 nm.

26. (Original) An apparatus according to Claim 25 wherein:  
the first, second, third, and fourth wavelengths measure oxyhemoglobin,  
deoxyhemoglobin, ferritin, and carbon dioxide concentration in tissue.

27. (Original) An apparatus according to Claim 26 further comprising:  
a processor coupled to the analyzer capable of noninvasively measuring the  
concentrations so that measurements are made continuously and without  
risk of infection, bleeding, blood loss, or invasive procurement  
procedures.

28. (Original) An apparatus according to Claim 26 further comprising:  
a processor coupled to the analyzer capable of measuring oxyhemoglobin,  
deoxyhemoglobin, ferritin, and carbon dioxide concentration for  
improving diagnosis, treatment including specificity and dosing, or  
prevention of a pathophysiologic condition.

29. (Original) An apparatus according to Claim 28 further comprising:  
a processor including a process for monitoring of exercise, aging, and related  
physiologic functions.

KOESTNER BERTANI LLP  
18662 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0260

30. (Original) An apparatus according to Claim 26 further comprising:  
a process executable in the processor capable of monitoring a condition and  
managing application of medication based on the monitoring.
31. (Original) An apparatus according to Claim 26 further comprising:  
a process executable in the processor capable of monitoring a condition and  
managing automated application of inspired oxygen levels to minimal  
oxygen level requirements of a patient to supply effective oxygenation  
based on the monitoring.
32. (Original) An apparatus according to Claim 26 further comprising:  
a process executable in the processor capable of measuring oxygen concentration  
in conditions of patients who are supplemented with additional  
concentrations of oxygen.
33. (Original) An apparatus according to Claim 26 further comprising:  
a process executable in the processor capable of assessing perfusion following  
surgery or organ transplantation.
34. (Original) An apparatus according to Claim 26 further comprising:  
a process executable in the processor capable of diagnosing stroke, transient  
ischemic attack, atherosclerosis, and anemia.
35. (Original) An optical sensor comprising:  
means positionable on a tissue for emitting near infrared light into the tissue at a  
plurality of selected wavelengths;  
means for detecting reflected light from the tissue, the means for detecting being  
positioned on the tissue removed from the emitting means but sufficiently  
close in proximity to the emitting means to contact the same general  
tissue;  
means for activating the optical source to emit the near infrared light; and

KOESTNER BERTANI LLP  
18662 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92612  
TEL (949) 251-0250  
FAX (949) 251-0250



means for controlling oscillation of the emitting means to emit a plurality of wavelengths that are selected to vary absorption amplitude and slope of a compound of interest within the tissue.

36. (Original) An optical sensor according to Claim 35 wherein:  
the means for controlling oscillation is a means for controlling power and temperature of the emitting means.

37. (Canceled)

38. (Canceled)

39. (Canceled)

KOESTNER BERTANI LLP  
18662 MACARTHUR BLVD.  
SUITE 400  
IRVINE, CA 92613  
TEL (949) 231-0250  
FAX (949) 231-0260